Posted by Michael Wonder on 29 Jan 2024
Rezzayo approved to treat adult patients with invasive candidiasis
29 January 2024 - The MHRA has today approved the medicine Rezzayo (rezafungin) to treat a fungal infection called invasive candidiasis.
This approval is supported by evidence from a randomised, double-blind, controlled phase 3 clinical trial involving 187 patients with invasive candidiasis.
